Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.
Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.
The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus
The kits aren't likely to enhance American Girl's bottom line in any significant way, yet the flood of press coverage painted the company as compassionate in a way that few such organizations are.
Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza
Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.
Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.
The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges
Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma
Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing
The drugmaker recently launched a DTC campaign for diabetes drug Trulicity, which generated $73.7 million in sales in the third quarter.
The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.
The drugmakers worked with Evoke Health to develop a campaign that would differentiate the third-in-class type-2 diabetes drug in an increasingly competitive market.
Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic
The search giant and the drugmaker will develop new tools to monitor the disease and improve patient outcomes.
The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision
Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.
CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP
The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.
The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.
Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.
The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.
Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year
Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google